Advertisement

Assessment of adherence to disease-modifying anti-rheumatic drugs in rheumatoid arthritis

  • Clélia Monchablon
  • Henri GondéEmail author
  • Sophie Pouplin
  • Rémi Varin
  • Olivier Vittecoq
  • Thierry Lequerré
Original Article
  • 33 Downloads

Abstract

Objectives

This work aimed to assess treatment adherence in rheumatoid arthritis patients with several tools and to identify factors associated with poor adherence.

Method

Between February and December 2015, 183 patients were included in this cross-sectional study. A homemade 23-item self-questionnaire was filled by patients during an outpatient consultation or a day hospitalization stay. Morisky Medication Adherence Scale (MMAS)-4, MMAS-8 and Girerd scores were extracted from this homemade questionnaire. Medication possession ratio (MPR) was then calculated. For identification of factors associated with nonadherence, patients were divided in two groups according to MMAS-8 results differentiating patients with good or bad adherence to treatments.

Results

Of the 183 patients, 59% received a combination of biologic and conventional synthetic disease-modifying drugs, 22% a biological treatment alone, and 19% a conventional DMARD alone. Respectively, 3%, 10%, and 7% were considered as low adherent according to MMAS-4, MMAS-8, and Girerd scores. MPR was calculated for 84/183 patients; 23% were low adherent. The need for a help in preparing the drugs (p = 0.05; OR = 6.12; 95% CI: 0.86 to 268.90) and concomitant diabetes (p < 0.001; OR = 0.045, 95% CI: 0.001 to 0.299) was higher in patients with good adherence. Presence of a patient’s relative reminding to take medications was associated with low adherence (p = 0.002; OR = 4.32, 95% CI: 1.41 to 13.11).

Conclusions

This study highlighted the difficulty of assessing treatment adherence in rheumatoid arthritis patients despite four different tools. Objective measures by MPR indicated a higher proportion of poor adherent patients than self-questionnaires.

Key Points

Proportion of patients considered as low adherent ranged from 3 to 27% according to the method of evaluation.

The use of a pillbox and/or the preparation of drugs by a patient’s relative was associated with good adherence.

The presence of a patient’s relative reminding to take medication was associated with low adherence.

Keywords

Adherence Medication Questionnaire Rheumatoid arthritis 

Notes

Compliance with ethical standards

Conflict of interest

T.L. has received research grants and/or honoraria from AbbVie, Amgen, BMS, Lilly, MSD, Novartis, Pfizer, Sanofi Aventis, and UCB. Other authors do not declare conflicts of interest.

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Supplementary material

10067_2019_4837_MOESM1_ESM.pdf (169 kb)
ESM 1 (PDF 168 kb)

References

  1. 1.
    Cramer JA, Roy A, Burrell A, Fairchild CJ, Fuldeore MJ, Ollendorf DA, Wong PK (2008) Medication compliance and persistence: terminology and definitions. Value Health 11:44–47CrossRefGoogle Scholar
  2. 2.
    Martin LR, Williams SL, Haskard KB, Dimatteo MR (2005) The challenge of patient adherence. Ther Clin Risk Manag 1:189–199PubMedPubMedCentralGoogle Scholar
  3. 3.
    Osterberg L, Blaschke T (2005) Adherence to medication. N Engl J Med 353:487–497CrossRefGoogle Scholar
  4. 4.
    Scott DL, Wolfe F, Huizinga TWJ (2010) Rheumatoid arthritis. Lancet 376:1094–1108CrossRefGoogle Scholar
  5. 5.
    de Achaval S, Suarez-Almazor ME (2010) Treatment adherence to disease-modifying antirheumatic drugs in patients with rheumatoid arthritis and systemic lupus erythematosus. Int J Clin Rheumatol 5:313–326CrossRefGoogle Scholar
  6. 6.
    Contreras-Yáñez I, Ponce De León S, Cabiedes J et al (2010) Inadequate therapy behavior is associated to disease flares in patients with rheumatoid arthritis who have achieved remission with disease-modifying antirheumatic drugs. Am J Med Sci 340:282–290CrossRefGoogle Scholar
  7. 7.
    Bluett J, Morgan C, Thurston L et al (2015) Impact of inadequate adherence on response to subcutaneously administered anti-tumour necrosis factor drugs: results from the Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate cohort. Rheumatology 54:494–499CrossRefGoogle Scholar
  8. 8.
    Morisky DE, Green LW, Levine DM (1986) Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care 24:67–74CrossRefGoogle Scholar
  9. 9.
    Morisky DE, Ang A, Krousel-Wood M, Ward HJ (2008) Predictive validity of a medication adherence measure in an outpatient setting. J Clin Hypertens 10:348–354CrossRefGoogle Scholar
  10. 10.
    Blum MA, Koo D, Doshi JA (2011) Measurement and rates of persistence with and adherence to biologics for rheumatoid arthritis: a systematic review. Clin Ther 33:901–913CrossRefGoogle Scholar
  11. 11.
    Tkacz J, Ellis L, Bolge SC, Meyer R, Brady BL, Ruetsch C (2014) Utilization and adherence patterns of subcutaneously administered anti-tumor necrosis factor treatment among rheumatoid arthritis patients. Clin Ther 36:737–747CrossRefGoogle Scholar
  12. 12.
    Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO 3rd, Birnbaum NS, Burmester GR, Bykerk VP, Cohen MD, Combe B, Costenbader KH, Dougados M, Emery P, Ferraccioli G, Hazes JM, Hobbs K, Huizinga TW, Kavanaugh A, Kay J, Kvien TK, Laing T, Mease P, Ménard HA, Moreland LW, Naden RL, Pincus T, Smolen JS, Stanislawska-Biernat E, Symmons D, Tak PP, Upchurch KS, Vencovský J, Wolfe F, Hawker G (2010) 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 62:2569–2581CrossRefGoogle Scholar
  13. 13.
    Girerd X, Hanon O, Anagnostopoulos K et al (2001) Assessment of antihypertensive compliance using a self-administered questionnaire: development and use in a hypertension clinic. Presse Med 30:1044–1048PubMedGoogle Scholar
  14. 14.
    Karve S, Cleves MA, Helm M, Hudson TJ, West DS, Martin BC (2009) Good and poor adherence: optimal cut-point for adherence measures using administrative claims data. Curr Med Res Opin 25:2303–2310CrossRefGoogle Scholar
  15. 15.
    Gossec L, Molto A, Romand X et al (2019) Recommendations for the assessment and optimization of adherence to disease-modifying drugs in chronic inflammatory rheumatic diseases: a process based on literature reviews and expert consensus. Joint Bone Spine 86:13–19CrossRefGoogle Scholar
  16. 16.
    Tan X, Patel I, Chang J (2014) Review of the four item Morisky Medication Adherence Scale (MMAS-4) and eight item Morisky Medication Adherence Scale (MMAS-8). Innov Pharm.  https://doi.org/10.24926/iip.v5i3.347
  17. 17.
    Hansen RA, Kim MM, Song L, Tu W, Wu J, Murray MD (2009) Comparison of methods to assess medication adherence and classify nonadherence. Ann Pharmacother 43:413–422CrossRefGoogle Scholar
  18. 18.
    van den Bemt BJF, Zwikker HE, van den Ende CHM (2012) Medication adherence in patients with rheumatoid arthritis: a critical appraisal of the existing literature. Expert Rev Clin Immunol 8:337–351CrossRefGoogle Scholar
  19. 19.
    Ho PM, Bryson CL, Rumsfeld JS (2009) Medication adherence: its importance in cardiovascular outcomes. Circulation 119:3028–3035CrossRefGoogle Scholar
  20. 20.
    Harley CR, Frytak JR, Tandon N (2003) Treatment compliance and dosage administration among rheumatoid arthritis patients receiving infliximab, etanercept, or methotrexate. Am J Manag Care 9:S136–S143PubMedGoogle Scholar
  21. 21.
    Kristensen LE, Saxne T, Nilsson J-A, Geborek P (2006) Impact of concomitant DMARD therapy on adherence to treatment with etanercept and infliximab in rheumatoid arthritis. Results from a six-year observational study in southern Sweden. Arthritis Res Ther 8:R174CrossRefGoogle Scholar
  22. 22.
    Voulgari PV, Alamanos Y, Nikas SN, Bougias DV, Temekonidis TI, Drosos AA (2005) Infliximab therapy in established rheumatoid arthritis: an observational study. Am J Med 118:515–520CrossRefGoogle Scholar
  23. 23.
    Morgan C, McBeth J, Cordingley L, Watson K, Hyrich KL, Symmons DP, Bruce IN (2015) The influence of behavioural and psychological factors on medication adherence over time in rheumatoid arthritis patients: a study in the biologics era. Rheumatology 54:1780–1791CrossRefGoogle Scholar
  24. 24.
    Vangeli E, Bakhshi S, Baker A, Fisher A, Bucknor D, Mrowietz U, Östör AJ, Peyrin-Biroulet L, Lacerda AP, Weinman J (2015) A systematic review of factors associated with non-adherence to treatment for immune-mediated inflammatory diseases. Adv Ther 32:983–1028CrossRefGoogle Scholar
  25. 25.
    Zink A, Listing J, Kary S, Ramlau P, Stoyanova-Scholz M, Babinsky K, von Hinueber U, Gromnica-Ihle E, Wassenberg S, Antoni C, Herzer P, Kekow J, Schneider M, Rau R (2005) Treatment continuation in patients receiving biological agents or conventional DMARD therapy. Ann Rheum Dis 64:1274–1279CrossRefGoogle Scholar
  26. 26.
    De Cuyper E, De Gucht V, Maes S et al (2016) Determinants of methotrexate adherence in rheumatoid arthritis patients. Clin Rheumatol 35:1335–1339CrossRefGoogle Scholar
  27. 27.
    Gadallah MA, Boulos DNK, Gebrel A et al (2015) Assessment of rheumatoid arthritis patients’ adherence to treatment. Am J Med Sci 349:151–156CrossRefGoogle Scholar
  28. 28.
    Anghel L-A, Farcaş AM, Oprean RN (2018) Medication adherence and persistence in patients with autoimmune rheumatic diseases: a narrative review. Patient Prefer Adherence 12:1151–1166CrossRefGoogle Scholar
  29. 29.
    Hill J, Bird H, Johnson S (2001) Effect of patient education on adherence to drug treatment for rheumatoid arthritis: a randomised controlled trial. Ann Rheum Dis 60:869–875PubMedPubMedCentralGoogle Scholar
  30. 30.
    Curkendall S, Patel V, Gleeson M, Campbell RS, Zagari M, Dubois R (2008) Compliance with biologic therapies for rheumatoid arthritis: do patient out-of-pocket payments matter? Arthritis Rheum 59:1519–1526CrossRefGoogle Scholar
  31. 31.
    Walsh JC, Mandalia S, Gazzard BG (2002) Responses to a 1 month self-report on adherence to antiretroviral therapy are consistent with electronic data and virological treatment outcome. AIDS 16:269–277CrossRefGoogle Scholar
  32. 32.
    Porteous T, Francis J, Bond C, Hannaford P (2010) Temporal stability of beliefs about medicines: implications for optimising adherence. Patient Educ Couns 79:225–230CrossRefGoogle Scholar
  33. 33.
    Tijhuis GJ, Kooiman KG, Zwinderman AH, Hazes JM, Breedveld FC, Vliet Vlieland TP (2003) Validation of a novel satisfaction questionnaire for patients with rheumatoid arthritis receiving outpatient clinical nurse specialist care, inpatient care, or day patient team care. Arthritis Rheum 49:193–199CrossRefGoogle Scholar
  34. 34.
    Murage MJ, Tongbram V, Feldman SR et al (2018) Medication adherence and persistence in patients with rheumatoid arthritis, psoriasis, and psoriatic arthritis: a systematic literature review. Patient Prefer Adherence 12:1483–1503CrossRefGoogle Scholar
  35. 35.
    Carter CT, Changolkar AK, Scott McKenzie R (2012) Adalimumab, etanercept, and infliximab utilization patterns and drug costs among rheumatoid arthritis patients. J Med Econ 15:332–339CrossRefGoogle Scholar

Copyright information

© International League of Associations for Rheumatology (ILAR) 2019

Authors and Affiliations

  • Clélia Monchablon
    • 1
  • Henri Gondé
    • 2
    Email author
  • Sophie Pouplin
    • 3
  • Rémi Varin
    • 2
  • Olivier Vittecoq
    • 4
  • Thierry Lequerré
    • 4
  1. 1.Department of PharmacyRouen University HospitalRouen CedexFrance
  2. 2.Normandie Univ, UNIROUEN, U1234 Inserm, Department of PharmacyRouen University HospitalRouen CedexFrance
  3. 3.Department of RheumatologyRouen University HospitalRouen CedexFrance
  4. 4.Normandie Univ, UNIROUEN, U1234 Inserm, Department of RheumatologyRouen University HospitalRouen CedexFrance

Personalised recommendations